U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07066280) titled 'Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer' on July 04.
Brief Summary: Acute radiation dermatitis (ARD) is the most common treatment-related adverse reaction following radiotherapy after modified radical mastectomy and/or prosthetic breast reconstruction in breast cancer patients. Moderate-to-severe ARD may compromise cosmetic outcomes and quality of life, and even impair radiotherapy efficacy. Current pharmacological prophylactic measures clinically employed - including topical corticosteroids, superoxide dismutase, and trolamine cream - demonstrate suboptimal efficacy and lack high-level eviden...